Kevin R. Flaherty

26.7k total citations · 1 hit paper
196 papers, 10.9k citations indexed

About

Kevin R. Flaherty is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, Kevin R. Flaherty has authored 196 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 181 papers in Pulmonary and Respiratory Medicine, 47 papers in Physiology and 25 papers in Epidemiology. Recurrent topics in Kevin R. Flaherty's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (163 papers), Sarcoidosis and Beryllium Toxicity Research (39 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (33 papers). Kevin R. Flaherty is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (163 papers), Sarcoidosis and Beryllium Toxicity Research (39 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (33 papers). Kevin R. Flaherty collaborates with scholars based in United States, Germany and United Kingdom. Kevin R. Flaherty's co-authors include Fernando J. Martínez, Susan Murray, Ella A. Kazerooni, Galen B. Toews, Barry H. Gross, Thomas V. Colby, William D. Travis, Eric S. White, Ganesh Raghu and Kevin K. Brown and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Annals of Internal Medicine.

In The Last Decade

Kevin R. Flaherty

190 papers receiving 10.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

2019 1.3k citations Kevin R. Flaherty, Athol U. Wells et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kevin R. Flaherty United States	55	9.1k	3.0k	1.2k	1.1k	1.1k	196	10.9k
Lisa Lancaster United States	36	8.8k 1.0×	3.1k 1.0×	1.1k 1.0×	677 0.6×	912 0.8×	100	10.3k
Marvin I. Schwarz United States	57	8.8k 1.0×	2.5k 0.8×	1.4k 1.2×	836 0.7×	883 0.8×	162	10.5k
Michael Kreuter Germany	46	5.8k 0.6×	2.0k 0.7×	776 0.7×	776 0.7×	1.4k 1.3×	347	8.5k
Jeffrey J. Swigris United States	39	6.6k 0.7×	2.5k 0.8×	1.5k 1.3×	1.1k 1.0×	466 0.4×	103	7.7k
Bruno Crestani France	58	6.7k 0.7×	2.1k 0.7×	1.3k 1.1×	997 0.9×	2.1k 1.9×	359	10.7k
Steven D. Nathan United States	56	12.1k 1.3×	3.5k 1.2×	1.4k 1.2×	619 0.5×	807 0.7×	319	14.3k
Paolo Spagnolo Italy	45	4.7k 0.5×	2.2k 0.7×	917 0.8×	564 0.5×	894 0.8×	179	6.2k
Carlyne D. Cool United States	58	8.9k 1.0×	1.9k 0.6×	1.2k 1.1×	639 0.6×	2.5k 2.2×	173	11.8k
Toby M. Maher United Kingdom	63	12.7k 1.4×	3.8k 1.3×	2.4k 2.1×	3.4k 2.9×	1.9k 1.8×	437	15.6k
Christopher J. Ryerson Canada	46	7.2k 0.8×	2.5k 0.8×	810 0.7×	1.1k 0.9×	393 0.4×	201	8.5k

Countries citing papers authored by Kevin R. Flaherty

Since Specialization

Citations

This map shows the geographic impact of Kevin R. Flaherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin R. Flaherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin R. Flaherty more than expected).

Fields of papers citing papers by Kevin R. Flaherty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin R. Flaherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin R. Flaherty. The network helps show where Kevin R. Flaherty may publish in the future.

Co-authorship network of co-authors of Kevin R. Flaherty

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin R. Flaherty. A scholar is included among the top collaborators of Kevin R. Flaherty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin R. Flaherty. Kevin R. Flaherty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Jennifer M., Ayodeji Adegunsoye, Janelle Vu Pugashetti, et al.. (2025). A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 211(10). 1785–1793. 1 indexed citations

Adegunsoye, Ayodeji, et al.. (2024). Use of Race-Specific Equations in Pulmonary Function Tests Impedes Potential Eligibility for Care and Treatment of Pulmonary Fibrosis. Annals of the American Thoracic Society. 21(8). 1156–1165. 7 indexed citations

Nathan, Steven D., Jürgen Behr, Vincent Cottin, et al.. (2024). Study Design and Rationale for the TETON-PPF Phase 3, Randomized, Controlled Clinical Trial of Inhaled Treprostinil in the Treatment of Progressive Pulmonary Fibrosis. SHILAP Revista de lepidopterología. 3(2). 100124–100124. 3 indexed citations

Cottin, Vincent, et al.. (2024). Study Design and Rationale for the TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis. A3760–A3760. 2 indexed citations

Pugashetti, Janelle Vu, J. Kim, Swaraj Bose, et al.. (2024). Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis. A1006–A1006.

Parker, Joseph M., Ian Glaspole, Lisa Lancaster, et al.. (2017). A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 197(1). 94–103. 90 indexed citations

Huang, Yong, Shwu‐Fan Ma, Milena S. Espíndola, et al.. (2017). Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 196(2). 208–219. 95 indexed citations

White, Eric S., Meng Xia, Susan Murray, et al.. (2016). Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine. 194(10). 1242–1251. 127 indexed citations

Salisbury, Margaret L., David A. Lynch, Edwin J.R. van Beek, et al.. (2016). Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes. American Journal of Respiratory and Critical Care Medicine. 195(7). 921–929. 96 indexed citations

10.

Sheth, Jamie, John A. Belperio, Michael C. Fishbein, et al.. (2016). Utility of Transbronchial vs Surgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease. CHEST Journal. 151(2). 389–399. 61 indexed citations

11.

Salisbury, Margaret L., Meng Xia, Yueren Zhou, et al.. (2015). Idiopathic Pulmonary Fibrosis. CHEST Journal. 149(2). 491–498. 69 indexed citations

12.

Raghu, Ganesh, Harold R. Collard, Kevin J. Anstrom, et al.. (2012). Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials. American Journal of Respiratory and Critical Care Medicine. 185(10). 1044–1048. 154 indexed citations

13.

Fell, Charlene D., Fernando J. Martínez, Lyrica X. Liu, et al.. (2010). Clinical Predictors of a Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 181(8). 832–837. 181 indexed citations

14.

Joshi, Amrita, Sameer R. Oak, Glenda Trujillo, et al.. (2009). Interleukin-17–mediated Immunopathogenesis in Experimental Hypersensitivity Pneumonitis. American Journal of Respiratory and Critical Care Medicine. 179(8). 705–716. 76 indexed citations

15.

Fell, Charlene D., Ella A. Kazerooni, Barry H. Gross, et al.. (2008). The Prognostic Value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 179(5). 402–407. 83 indexed citations

16.

Huang, Steven K., Scott H. Wettlaufer, Cory M. Hogaboam, et al.. (2007). Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine. 177(1). 66–74. 60 indexed citations

17.

Muro, Andrés F., Federico A. Moretti, Bethany B. Moore, et al.. (2007). An Essential Role for Fibronectin Extra Type III Domain A in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 177(6). 638–645. 242 indexed citations

18.

Flaherty, Kevin R., Adin‐Cristian Andrei, Susan Murray, et al.. (2006). Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 174(7). 803–809. 296 indexed citations

19.

Lama, Vibha N., Kevin R. Flaherty, Galen B. Toews, et al.. (2003). Prognostic Value of Desaturation during a 6-Minute Walk Test in Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine. 168(9). 1084–1090. 394 indexed citations

20.

Flaherty, Kevin R., John J. Wald, Idelle M. Weisman, et al.. (2001). Unexplained Exertional Limitation. American Journal of Respiratory and Critical Care Medicine. 164(3). 425–432. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact